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numerous organ manifestations, involvement of the upper and lower gastrointestinal tract (GIT) 
appears to be the most frequent with regard to the clinical symptoms. However, as the frequency and 
clinical relevance of GI involvement in patients with SSc are not known in detail, the German network 
of the Systemic Sclerosis (DNSS) has developed a detailed questionnaire to evaluate the extent and 
profile of gastrointestinal involvement in SSc patients. 
Methods: The multi- symptom questionnaire was used at baseline and after one year in registered 
patients of the DNSS. In addition the results were compared with gastrointestinal disorders in patients 
with SSc and other rheumatic diseases, as well as with the medical history of the patients. In total, 90 
patients were included in the study. 
Results: The results of the study show that in reality a much higher (nearly all) percentage of (98,9%) 
patients than expected suffer from GI- symptoms, regardless of the stage of their disease. Of these, 
meteorism (87,8%) was the most common followed by coughing/ sore voice (77,8%), heartburn 
(daytime 68,9%, nighttime 53,3%), diarrhea (67,8%), stomach ache (68,9%) and nausea (61,1%). 
Conclusions: Although SSc patients were treated according to the respective recommendations, only 
limited improvements with regard to GI- symptoms could be achieved after one year of follow up. In 
addition, the study revealed that the multi- symptom questionnaire is a useful tool to contribute to 
identify the gastrointestinal sequelae in systemic sclerosis. 
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Abstract: Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease. Of the 
numerous organ manifestations, involvement of the upper and lower gastrointestinal tract (GIT) 
appears to be the most frequent with regard to the clinical symptoms. However, as the frequency and 
clinical relevance of GI involvement in patients with SSc are not known in detail, the German network 
of the Systemic Sclerosis (DNSS) has developed a detailed questionnaire to evaluate the extent and 
profile of gastrointestinal involvement in SSc patients. 
Methods: The multi- symptom questionnaire was used at baseline and after one year in registered 
patients of the DNSS. In addition the results were compared with gastrointestinal disorders in patients 
with SSc and other rheumatic diseases, as well as with the medical history of the patients. In total, 90 
patients were included in the study. 
Results: The results of the study show that in reality a much higher (nearly all) percentage of (98,9%) 
patients than expected suffer from GI- symptoms, regardless of the stage of their disease. Of these, 
meteorism (87,8%) was the most common followed by coughing/ sore voice (77,8%), heartburn 
(daytime 68,9%, nighttime 53,3%), diarrhea (67,8%), stomach ache (68,9%) and nausea (61,1%). 
Conclusions: Although SSc patients were treated according to the respective recommendations, only 
limited improvements with regard to GI- symptoms could be achieved after one year of follow up. In 
addition, the study revealed that the multi- symptom questionnaire is a useful tool to contribute to 
identify the gastrointestinal sequelae in systemic sclerosis. 
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Introduction 
 
Systemic sclerosis (SSc) is a generalised chronic autoimmune connective tissue disease with a 
prevalence of about 20:100.000. Females are affected 4.6 times more than males [1]. The 
pathophysiology of SSc, especially of the GIT, is known only to a limited extent. This idea is not only 
based on clinical experience but on the only slowly increasing knowledge of pathways leading to 
increased fibrosis, altered regulation of microcirculation as well as of humoral and cellular changes 
similar to the alterations observed in SSc skin [2,3]. Clinically, SSc can present as diffuse (skin 
thickening proximal of the elbow and knee) and limited (skin thickening restricted to areas distal of 
elbow and knee) disease. 
In literature, the Raynaud- phenomenon and skin thickening are the most common and prominent 
characteristics in patients with SSc, but some data [4] supported also the hypothesis that involvement 
of the GI- tract might be more frequent than expected. Fibrotic changes due to increased deposition of 
collagen and other extracellular matrix components in the upper and lower GIT lead to dysmotility, 
malabsorption, malnutrition and dilation of the intestine. Main symptoms are meteorism, dysmotility of 
the esophagus, heartburn and dysphagia. In addition coughing and a sore voice can occur. 
Furthermore, constipation and diarrhea have been reported. In severe cases, gastrointestinal 
manifestations can result in lethal complications such as pseodoobstruction similar to severe 
cardiopulmonary or renal involvement. Therefore, the aim of the study was to elucidate a detailed 
profile of gastrointestinal involvement in patients with SSc using a newly designed questionnaire. 
 
 
Methods and Patients  
 
Based on the research plan of the German network for systemic sclerosis (DNSS), we developed a 
multi- symptom questionnaire which consisted of 12 main items (symptoms) addressing the activity 
and frequency of known and potential GI- symptoms. Each of these items was subdivided in time and 
frequency (scaled in continuously, daily, several times, a few days in the month, rare, never [Figure 
1]). 
Another subitem was the consumption of alcohol and tobacco. 
Patients with the clinical diagnosis of SSc with regard to the classification criteria of the American 
College of Rheumatology [5] or MCTD [6] were included into the study. 
 
SSc patients were subclassified into the group of diffuse cutaneous SSc (dcSSc), of limited cutaneous 
SSc (lcSSc) and of mixed connective tissue disease (MCTD) patients with dominant SSc features. In 
addition, the patients had to be able to understand and answer the questionnaire completely. The 
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recruitment period was between 2005- 2007 and to illustrate a real- life situation, the inclusion of 
patients was based on patient- need and not on order or patients- call. 90 patients, 75 females and 15 
males, with a mean age of 57,4 years were included into the study. 55 patients with lcSSc, 16 with 
dcSSc, 16 with MCTD and 3 with an undifferentiated connective tissue disease (mixed connective 
tissue disease and undifferentiated – with allotments of systemic sclerosis) could be enclosed.  
Until present, 34 patients could be included in the follow up after one year. Of these 31 female patients 
(91,2%) and 3 males (8,8%) were included with a mean age of 55,6 years. 4 patients suffered from a 
diffuse and 19 from the limited subtype of SSc. Enclosed were also 8 patients with a mixed connective 
tissue disease (MCTD) and 3 with an undifferentiated connective tissue disease. For the comparison 
with the 34 SSc follow up patients, 34 patients with another inflammatory rheumatic disease such as 
rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis were included. 82,4% of 
these patients with another rheumatologic disease were female and 17,6% male. The patients that 
were enrolled in the control group had a mean age of 60,9 years. 
 
Results 
 
Gastrointestinal involvement in patients with SSc 
 
Although earlier investigations had reported that GI- symptoms are a significant problem for patients 
with SSc, the results of our study indicate that when examining GI- symptoms on a detailed basis 
nearly all of these patients with SSc suffer from GI- symptoms. When applying the multi- symptom 
questionnaire to these patients (83,3% were female and the mean age was 57,4 years) 98,9% 
reported to suffer from any kind of gastrointestinal complications. Only one SSc patient (1,1%) did not 
report any gastrointestinal symptom. Nutritive effects did not appear to contribute significantly to this 
high frequency of GI- symptoms as only 15 patients consumed alcohol occasionally and none 
regularly. Similarly, only 9 patients smoked on a regular basis, 5 occasionally. 
The most frequent symptom of gastrointestinal involvement was meteorism (87,8%) followed by 
coughing/ sore voice (77,8%), heartburn (daytime 68,9%, nighttime 53,3%), diarrhea (67,8%), 
stomach ache (68,9%) and nausea (61,1%). Almost every second patient (48,9%) suffered from 
constipation. Less frequent symptoms were vomiting (36,7%) and weight loss (27,8%). Fecal 
incontinence was reported by 22,2%. The main manifestations are summarized in Figure 2. 
 
Differences in GI- symptoms in patients with limited SSc, diffuse SSc and MCTD 
 
When evaluating the different SSc subsets, distinct differences could be revealed (Figure 3). The most 
frequent and prominent symptoms in patients with dcSSc were meteorism (80,0%), daytime heartburn 
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(80,0%), coughing/ sore voice (80,0%) and stomach ache (80,0%). Nighttime heartburn (73,3%), 
diarrhea (73,3%) and nausea (60,0%) were reported also very often. Less frequent symptoms were 
constipation (46,7%), vomiting (33,3%), weight loss <=9 kg (26,7%) and fecal incontinence (13,3 %). 
 
Most interestingly, symptoms originating from the upper GI were named less frequently by patients 
with lcSSc than patients with dcSSc. The most prominent differences between dcSSc and lcSSc were 
nighttime heartburn (-24,2%), daytime heartburn (-14,5%) and stomach ache (-14,5%). Also diarrhea 
(-6,0%) was reported less frequent from patients with lcSSc. In contrast, fecal incontinence and 
(+14,0%) meteorism (+7,3%) were reported more frequently by patients with lcSSc.  
No differences between the SSc subsets could be found for coughing/ sore voice (-1,8%), nausea (-
1,8%), vomiting (+3,1%), constipation (+4,2%) and weight loss <=9 kg (+4,2%).  
The frequency of distinct symptoms of the upper GIT appeared also to be more similar between 
dcSSc and MCTD. In patients with MCTD, daytime heartburn (+1,3%) and coughing/ sore voice 
(+1,3%) were named as frequent as in dcSSC patients. No differences for the lower GIT could be 
found for: fecal incontinence (-0,8%), diarrhea (+1,7%), constipation (+3,3%) and weight loss <= 9kg 
(+4,6%).  
In contrast, differences were reported for meteorism (+13,8%), nighttime heartburn (-10,8%), vomiting 
(+10,5%), nausea (+8,8%) and stomach ache (-5,0%).  
 
Follow up of gastrointestinal involvement after one year 
 
As it could be expected that evaluation and adequate treatment of GI- symptoms by a rheumatologist 
and/ or gastroenterologist might result in an alteration and/ or improvement of GI- symptoms, the SSc 
patients were re- evaluated on a routine basis after one year. The results of the baseline visit and the 
data of the follow up visit could be evaluated for 34 patients until present as shown in Figure 4. When 
compared to the initial examination, the profile of the patients was similar and only 3 were still 
consuming tobacco regularly and 1 occasionally. The patient without any symptoms at the baseline 
visit did not present again in the outpatient clinic. Interestingly another patient with GI-disorders in the 
first year did report no GI-symptoms in the follow up visit any more. 
The most prominent changes (Table 1) in the pattern of GI- symptoms after one year of follow up were 
the decrease in nausea (-14,7%) and nighttime heartburn (-11,8%), followed by a decrease of weight 
loss (-8,4%), daytime heartburn (-5,9%), vomiting (-5,9%) and coughing/ sore voice (-5,9%). 
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Disorders  baseline visit (%) Change rate* follow up visit (%)  
Meteorism 82,4 + 88,2  
Coughing/ sore voice 82,4 - 76,5  
Diarrhea 79,4 ~ 79,4  
Stomach ache 73,5 ~ 76,5  
Heartburn (day) 73,5 - 67,6  
Nausea 67,6 -- 52,9  
Heartburn (night) 61,8 -- 50  
Constipation 50 ++ 67,6  
Vomiting 44,1 - 38,2  
Weight loss <=9 kg 29 - 20,6  
Fecal incontinence 23,5 ~ 23,5  
Treatment with PPI 82,4 ~ 84,5  
*   ~ = +/- 5% 
    +/- = +/- 5-10% 
    ++/--  = +/- >10% 
 
Table 1 Results of baseline visit and follow up visit shown in percent (+/-). 
 
In contrast, constipation (+17,6%) and meteorism (+5,8%) increased considerably. Without significant 
change were the frequency for diarrhea (0,0%) fecal incontinence (0,0%) and stomach ache (+3,0%).  
Of note, this development could not be associated with a change in reflux therapy as at baseline 
82,4% of the patients received already a treatment with proton pump inhibitors (PPI) and at time of  
follow up 84,5% received this treatment. 
 
Comparison of the DNSS questionnaire and medical history 
 
Owing to the lower frequency of GI- symptoms in literature and our study, we also compared the 
differences between the medical history of the 90 patients performed by the respective physicians and 
the results of the questionnaire (Figure 5). Of note, gastrointestinal symptoms were documented much 
less frequently by physicians who evaluated the medical history on a routine basis, i.e. heartburn 
(49,4%), stomach ache (29,9%), nausea (9,2%), constipation (25,3%), diarrhoea (26,4%), meteorism 
(37,9%) and weight loss (18,4%) underlining the need for a more thorough GI- evaluation in daily 
routine clinical practice. 
 
Differences in gastrointestinal involvement between SSc patients and patients with 
other rheumatic diseases 
 
To evaluate whether GI- symptoms are of a more general nature in patients with rheumatic diseases 
versus being specific for SSc, we applied the questionnaire also to patients with other rheumatic 
diseases (Figure 6). The data (Table 2) show that patients with other rheumatic diseases also suffer 
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from gastrointestinal disorders. They also reported some symptoms with a similar frequency: 
meteorism (79,4%), diarrhea (79,4%), constipation (55,9%) and fecal incontinence (23,5%).  
 
Disorders SSc baseline (%) Change rate* Patients with other 
rheumatic diseases (%) 
Meteorism 82,4 ~ 79,4 
Coughing/ sore voice 82,4 - 73,5 
Diarrhoea 79,4 ~ 79,4 
Stomach ache 73,5 ~ 70,6 
Heartburn (day) 73,5 -- 55,9 
Nausea 67,6 -- 55,9 
Heartburn (night) 61,8 -- 32,4 
Constipation 50 + 55,9 
Vomiting 44,1 - 38,2 
Weight loss <=9 kg 29 -- 14,7 
Fecal incontinence 23,5 ~ 23,5 
Medical treatment 82,4 -- 55,9 
*   ~ = +/- 5% 
    +/- = +/- 5-10% 
    ++/--  = +/- >10% 
 
Table 2: Patients with other rheumatic diseases 
 
In contrast, symptoms associated with the upper GIT were noted less frequently in non- SSc 
rheumatologic patients than in patients with SSc with weight loss 14,7% being the most prominent 
difference followed by heartburn (daytime: 55,9%, nighttime: 32,4%), coughing/ sore voice 73,5%, 
stomach ache 70,6%, vomiting 38,2% and nausea 55,9%. 
This spectrum of sequelae was not age and gender related as also 82% were female and the mean 
age of this group was 60,9 years. 
 
 
Discussion 
 
Although there have been several publications addressing the frequency and intensity of GI- 
symptoms in SSc patients, the most important result of the detailed evaluation by a disease- specific 
questionnaire is the much higher frequency (up to 99%) of GI- symptoms in a rheumatology GI- center 
setting. 
As the frequency of GI involvement is very high - similar or even higher than others such as Raynaud- 
phenomenon and skin thickening - the data underline the need for a detailed GI evaluation early in the 
course of the disease, also because the involvement of the GIT in patients with SSc influences 
significantly the morbidity and mortality of these patients [7]. There is also a correlation between the 
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intensity of symptoms and their well being [8]. In contrast to the most published studies addressing 
gastrointestinal involvement [4, 8, 9], meteorism is the most frequent symptom (87,4%) in our cohort. 
But also coughing/ sore voice (77,0%) and heartburn (daytime 69,0%, nighttime 55,2%) were 
mentioned by patients with systemic sclerosis very often. 
Cohen et al. [10] postulated a concept of the underlying pathomechanisms with regard to these 
symptoms: neural lesions may occur early and can cause an irreversible disruption of the esophageal 
motor function followed by development of significant smooth muscle atrophy. The associated reduced 
esophageal motility thereafter contributes to gastroesophageal reflux [11], heartburn, esophageal 
strictures, sore throat and even continuous microaspiration followed by pneumonia. Whether this 
dysfunction might also lead to a bronchospasmic reaction, restrictive lung disease and a pulmonary 
fibrosis, is not known yet [12]. 
Of note, Weber et al. found that gastrointestinal symptoms do not always correlate with the results of 
GI examinations [13]. 
Our patients also reported frequently stomach ache (67,8%) and vomiting (60,9%). An explanation for 
the pathomechanism of gastric dysmotility that could lead to these symptoms was developed by 
Sjögren et al.: Replacement of normal smooth muscles by fibrous connective tissue based on vascular 
damage (grade 0), neurogenic impairment (grade 1) and finally myogenic dysfunction (grade 2) 
[12,14] have been suggested as underlying causes. 
In a similar way, stomach dysmotility and dysfunction of the small intestine may be the underlying 
causes for gastroparesis, malnutrition and weight loss [12].  
Recently, Czirjak et al. [9] described gastrointestinal tract- related lethal cases due to bleeding from 
watermelon stomach (gastric vascular ectasia), dysmotility and malabsorption. Another complication of  
vascular ectasia and incessant hemorrhages is chronic anemia and even death [15]. 
Our real- life SSc outpatient results of a very frequent involvement of the upper GIT differ also in some 
patients from the regression model of Chung et al. [15]. In their study esophageal dysfunction was not 
identified as a dominant symptom for SSc patients admitted to hospital or for those who died in 
hospital. They also reported that aspiration pneumonitis as a complication of esophageal dysfunction 
was more common. This leads to the assumption that the effects of esophageal dysmotility in SSc 
patients may be higher than estimated by the regression models. Similarly, there are distinct 
differences with regard to the involvement of the lower GIT when compared to other studies [8,14]. 
Almost every second patient (48,9%) reported to suffer from constipation in our questionnaire. 
Usually this is based on dysmotility with a delayed colonic transit [16] and increased intestinal 
permeabilities [18] and a feeling of bloating and meteorism, which was also the most prominent 
symptom in our cohort (87,8%). 
Impairment of the anorectum leads to symptoms such as fecal incontinence. According to the data 
obtained from our patients the prevalence (22,2%) of fecal incontinence is lower than expected. In this 
aspect our results are similar to those of the studies mentioned above [8,9]. 
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However it needs to be considered that fecal incontinence might not have been mentioned by 
sensitive patients even if it existed as revealed by the questionnaire [11]. 
In summary the increase of fibrosis and the disturbed regulation of microcirculation as well as humoral 
and cellular changes is most likely the underlying cause for the impairment of the GIT in patients with 
systemic sclerosis [3]. 
After one year distinct alterations in symptoms could be observed. The most prominent changes could 
be found with regard to decrease of nausea (-14,7%) and nighttime heartburn (-11,8%). In contrast, 
symptoms such as constipation (+17,6%) and meteorism (+5,8%) were reported more frequently.  
When comparing SSc subsets, distinct differences could be revealed. The majority of the symptoms 
listed in our questionnaire were reported with a higher frequency in patients with either dcSSc or 
MCTD in contrast to patients with lcSCC. Most prominent differences were found for nighttime 
heartburn (-24,2%), daytime heartburn (-14,5%) and stomach ache (-14,5%). The result of the 
comparison of the subsets points out that MCTD and dcSSc are more alike in development of GI- 
symptoms than lcSSc. In addition, Walker et al. [17] reported particular
 
organ manifestations in the 
subsets of SSc which are associated with distinct clinical disorders. Nevertheless the data of our SSc 
patients illustrate the more diffuse/ systemic character of the dcSSc subset.  
As recent studies [17,19] suggested that there might not be distinct differences between 
gastrointestinal disorders in the subtypes of connective tissue disease, our questionnaire revealed the 
few but distinct differences in the individual occurrence of symptoms between the subtypes, with 
nighttime heartburn being the most prominent [73,3% (dcSSc); 49,1% (lcSSC); 62,5% (MCTD)]. 
 
It needs to be noted that our study has some limitations due to the lack of a full- range comparison of 
the sequelae with technical procedures such as 24- pH monitoring, gastroesophageal endoscopy, 
radionuclide assays but in our experience in a routine setting the patients are more than hesitant to 
undergo all of these strenuous procedures if not urgently needed. 
 
In summary this is the first study applying and evaluating a detailed GI- questionnaire on patients with 
SSc in Western Europe including a follow up reexamination. 
Our results support the hypothesis that besides the well known Raynaud- phenomenon and skin 
thickening, gastrointestinal disorders in patients with SSc are more frequent than expected and their 
evaluation should be done at the first time of presentation of the patient. The results also illustrate the 
need for a detailed interview of the patient as standard medical records do not match the results of the 
questionnaire. 
This may be based on the fact that patients (and physicians) often do not realize the correlation 
between the gastrointestinal symptoms and their autoimmune disease. 
Therefore, the presented questionnaire is a useful tool to contribute to the timely evaluation of 
gastrointestinal involvement in systemic sclerosis and thereby to optimize life quality of patients. 
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Figure legends: 
 
Figure 1: Detailed multi- symptom questionnaire (Original in German, trade names of drugs according to the German 
market). 
 
Figure 2: Gastrointestinal symptoms of SSc patients at time of first presentation. Drugs were taken by approximately 
70% of these patients. 
 
Figure 3: Differences in GI- disorders in patients that suffer from diffuse SSc, limited SSc and MCTD. Diffuse SSc 
patients received more frequent medication for those sequelae. 
 
Figure 4: Gastrointestinal symptoms in patients with SSc after one year of follow up. 
 
Figure 5: Comparison DNSS questionnaire and medical history 
 
Figure 6: Comparison GI- disorders between SSc patients and patients with other rheumatic diseases 
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